The relationship between erectile dysfunction and cardiovascular disease. Part II

The role of PDE-5 inhibition in sexual dysfunction and cardiovascular disease

Vishal Kapur, Christopher Chien, Justin E. Fuess, Ernst R. Schwarz

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

Erectile dysfunction (ED) is a sensitive indicator of wider arterial insufficiency and an early correlate for the presence of ischemic heart disease. Among patients with coronary artery disease, prevalence reports of ED range from 42% to 75%. The US Food and Drug Administration has approved 3 phosphodiesterase-5 (PDE-5) inhibitors for treatment of male sexual dysfunction: sildenafil, tadalafil, and vardenafil. PDE-5 inhibitors also have cardiovascular effects. They inhibit PDE-5 enzymes in pulmonary vasculature, which causes vasodilation that decreases pulmonary vascular pressure. Sildenafil is approved for treatment of patients with pulmonary hypertension. PDE-5 inhibition with sildenafil improves cardiac output by balancing pulmonary and systemic vasodilation, and augments and prolongs the hemodynamic effects of inhaled nitric oxide in patients with chronic congestive heart failure and pulmonary hypertension. In vivo and in vitro studies are examining the possible beneficial effects of PDE-5 inhibitors in conditions such as myocardial infarction and endothelial dysfunction.

Original languageEnglish (US)
Pages (from-to)187-195
Number of pages9
JournalReviews in Cardiovascular Medicine
Volume9
Issue number3
StatePublished - Jun 2008
Externally publishedYes

Fingerprint

Type 5 Cyclic Nucleotide Phosphodiesterases
Phosphodiesterase 5 Inhibitors
Erectile Dysfunction
Cardiovascular Diseases
Pulmonary Hypertension
Vasodilation
Lung
United States Food and Drug Administration
Cardiac Output
Myocardial Ischemia
Blood Vessels
Coronary Artery Disease
Nitric Oxide
Heart Failure
Hemodynamics
Myocardial Infarction
Pressure
Enzymes
Therapeutics
Sildenafil Citrate

Keywords

  • Endothelial dysfunction
  • Erectile dysfunction
  • Heart failure
  • Myocardial infarction
  • PDE-5 inhibitors
  • Pulmonary hypertension

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

The relationship between erectile dysfunction and cardiovascular disease. Part II : The role of PDE-5 inhibition in sexual dysfunction and cardiovascular disease. / Kapur, Vishal; Chien, Christopher; Fuess, Justin E.; Schwarz, Ernst R.

In: Reviews in Cardiovascular Medicine, Vol. 9, No. 3, 06.2008, p. 187-195.

Research output: Contribution to journalArticle

@article{e9bb63080a38447a809b6024857d1d43,
title = "The relationship between erectile dysfunction and cardiovascular disease. Part II: The role of PDE-5 inhibition in sexual dysfunction and cardiovascular disease",
abstract = "Erectile dysfunction (ED) is a sensitive indicator of wider arterial insufficiency and an early correlate for the presence of ischemic heart disease. Among patients with coronary artery disease, prevalence reports of ED range from 42{\%} to 75{\%}. The US Food and Drug Administration has approved 3 phosphodiesterase-5 (PDE-5) inhibitors for treatment of male sexual dysfunction: sildenafil, tadalafil, and vardenafil. PDE-5 inhibitors also have cardiovascular effects. They inhibit PDE-5 enzymes in pulmonary vasculature, which causes vasodilation that decreases pulmonary vascular pressure. Sildenafil is approved for treatment of patients with pulmonary hypertension. PDE-5 inhibition with sildenafil improves cardiac output by balancing pulmonary and systemic vasodilation, and augments and prolongs the hemodynamic effects of inhaled nitric oxide in patients with chronic congestive heart failure and pulmonary hypertension. In vivo and in vitro studies are examining the possible beneficial effects of PDE-5 inhibitors in conditions such as myocardial infarction and endothelial dysfunction.",
keywords = "Endothelial dysfunction, Erectile dysfunction, Heart failure, Myocardial infarction, PDE-5 inhibitors, Pulmonary hypertension",
author = "Vishal Kapur and Christopher Chien and Fuess, {Justin E.} and Schwarz, {Ernst R.}",
year = "2008",
month = "6",
language = "English (US)",
volume = "9",
pages = "187--195",
journal = "Reviews in Cardiovascular Medicine",
issn = "1530-6550",
publisher = "MedReviews LLC",
number = "3",

}

TY - JOUR

T1 - The relationship between erectile dysfunction and cardiovascular disease. Part II

T2 - The role of PDE-5 inhibition in sexual dysfunction and cardiovascular disease

AU - Kapur, Vishal

AU - Chien, Christopher

AU - Fuess, Justin E.

AU - Schwarz, Ernst R.

PY - 2008/6

Y1 - 2008/6

N2 - Erectile dysfunction (ED) is a sensitive indicator of wider arterial insufficiency and an early correlate for the presence of ischemic heart disease. Among patients with coronary artery disease, prevalence reports of ED range from 42% to 75%. The US Food and Drug Administration has approved 3 phosphodiesterase-5 (PDE-5) inhibitors for treatment of male sexual dysfunction: sildenafil, tadalafil, and vardenafil. PDE-5 inhibitors also have cardiovascular effects. They inhibit PDE-5 enzymes in pulmonary vasculature, which causes vasodilation that decreases pulmonary vascular pressure. Sildenafil is approved for treatment of patients with pulmonary hypertension. PDE-5 inhibition with sildenafil improves cardiac output by balancing pulmonary and systemic vasodilation, and augments and prolongs the hemodynamic effects of inhaled nitric oxide in patients with chronic congestive heart failure and pulmonary hypertension. In vivo and in vitro studies are examining the possible beneficial effects of PDE-5 inhibitors in conditions such as myocardial infarction and endothelial dysfunction.

AB - Erectile dysfunction (ED) is a sensitive indicator of wider arterial insufficiency and an early correlate for the presence of ischemic heart disease. Among patients with coronary artery disease, prevalence reports of ED range from 42% to 75%. The US Food and Drug Administration has approved 3 phosphodiesterase-5 (PDE-5) inhibitors for treatment of male sexual dysfunction: sildenafil, tadalafil, and vardenafil. PDE-5 inhibitors also have cardiovascular effects. They inhibit PDE-5 enzymes in pulmonary vasculature, which causes vasodilation that decreases pulmonary vascular pressure. Sildenafil is approved for treatment of patients with pulmonary hypertension. PDE-5 inhibition with sildenafil improves cardiac output by balancing pulmonary and systemic vasodilation, and augments and prolongs the hemodynamic effects of inhaled nitric oxide in patients with chronic congestive heart failure and pulmonary hypertension. In vivo and in vitro studies are examining the possible beneficial effects of PDE-5 inhibitors in conditions such as myocardial infarction and endothelial dysfunction.

KW - Endothelial dysfunction

KW - Erectile dysfunction

KW - Heart failure

KW - Myocardial infarction

KW - PDE-5 inhibitors

KW - Pulmonary hypertension

UR - http://www.scopus.com/inward/record.url?scp=54049112309&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=54049112309&partnerID=8YFLogxK

M3 - Article

VL - 9

SP - 187

EP - 195

JO - Reviews in Cardiovascular Medicine

JF - Reviews in Cardiovascular Medicine

SN - 1530-6550

IS - 3

ER -